... is the first leg of our program to evaluate the utility of NAV5001 in DLB, the leading form of dementia after Alzheimer's disease and an important potential indication for NAV5001 medically and commercially" "This collaborative ...
http://eon.businesswire.com/news/eon/20130403006199/en/Navidea-Collaborator-Molecular-Neuroimaging-Enroll-Subject-NAV5001
http://eon.businesswire.com/news/eon/20130403006199/en/Navidea-Collaborator-Molecular-Neuroimaging-Enroll-Subject-NAV5001
No comments:
Post a Comment